Imaging response during therapy with radium-223 (Ra-223) for castration-resistant prostate cancer (CRPC) with bone metastases (BM): A multicenter analysis.

被引：3
|
作者：
Omlin, Aurelius Gabriel
Daugaard, Gedske
Peer, Avivit
Reichegger, Hermann
Neumann, Avivit
Rosenbaum, Eli
Desax, Marie-Claire
Neiman, Victoria
Petersen, Peter Meidahl
Mueller, Joachim
Cathomas, Richard
Gottfried, Maya
Sarid, David
Gez, Eli
Mermershtain, Wilmosh
Rouvinov, Keren
Mortensen, Jann
Gillessen, Silke
Keizman, Daniel
机构：
[1] Kantonsspital St Gallen, St Gallen, Switzerland
[2] Copenhagen Univ Hosp, Copenhagen, Denmark
[3] Rambam Hlth Care Campus, Haifa, Israel
[4] Cantonal Hosp St Gallen, St Gallen, Switzerland
[5] Rambam Med Ctr, Dept Oncol, Haifa, Israel
[6] Rabin Med Ctr, Dept Oncol, Petah Tiqwa, Israel
[7] Rabin Med Ctr, Davidoff Canc Ctr, Petach-Tikva, Israel
[8] Rigshosp, Dept Oncol, Copenhagen, Denmark
[9] Kantonsspital Chur, Chur, Switzerland
[10] Meir Med Ctr, Lung Canc Unit, Kefar Sava, Israel
[11] Ichilov Hosp, Sourasky Med Ctr, Tel Aviv, Israel
[12] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[13] Soroka Med Ctr, Beer Sheva, Israel
[14] Rigshosp, Nucl Med & PET, Dept Clin Physiol, Copenhagen, Denmark
[15] Tel Aviv Univ, Sackler Sch Med, Div Oncol, Meir Med Ctr,Genitourinary Oncol Serv, Kefar Sava, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5057
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging
    Iizuka, Junpei
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 16 - 23
  • [32] Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases
    Vogelzang, Nicholas J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (08) : 809 - 819
  • [33] Radium-223 for the treatment of castration-resistant prostate cancer
    El-Amm, Joelle
    Aragon-Ching, Jeanny B.
    ONCOTARGETS AND THERAPY, 2015, 8 : 1103 - 1109
  • [34] External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial
    Paganelli, G.
    Rossetti, C.
    Aglietta, M.
    Messina, C.
    Versari, A.
    Michalski, J. M.
    O'Sullivan, J. M.
    Parker, C.
    Garcia-Vargas, J. E.
    Sartor, A.
    Finkelstein, S. E.
    ANNALS OF ONCOLOGY, 2015, 26 : 62 - 62
  • [35] Ra-223 alpha-Therapy in Patients with Bone Metastases from Castration-resistant Prostate Cancer
    Jessome, Rebecca
    JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2015, 46 (02) : 156 - 161
  • [36] The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases
    Liu, Alex J.
    Kosiorek, Heidi E.
    Ueberroth, Benjamin E.
    Jaeger, Ellen
    Ledet, Elisa
    Kendi, Ayse T.
    Tzou, Katherine
    Quevedo, Fernando
    Choo, Richard
    Moore, Cassandra N.
    Ho, Thai H.
    Singh, Parminder
    Keole, Sameer R.
    Wong, William W.
    Sartor, Oliver
    Bryce, Alan H.
    PROSTATE, 2022, 82 (12): : 1202 - 1209
  • [37] The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases
    Ram, Prasanna
    Mandal, Swarnendu
    Das, Manoj K.
    Nayak, Prasant
    PROSTATE, 2023, 83 (06): : 613 - 613
  • [38] 3-year safety follow-up of Radium-223 Dichloride (Ra-223) in patients (Pts) with Castration-Resistant Prostate Cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Kramer, M. W.
    Kuczyk, M. A.
    Parker, C.
    Vogelzang, N.
    Sartor, O.
    Coleman, R. E.
    Fang, F.
    Skjorestad, I
    Nilsson, S.
    Oncology Research and Treatment, 2015, 38 : 266 - 266
  • [39] Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who had prior or no-prior docetaxel in the phase 3 ALSYMPCA trial
    Koenig, F.
    Vogelzang, N. J.
    Helle, S. I.
    Johannessen, D. C.
    O'Sullivan, J. M.
    Garcia-Vargas, J.
    Tear, C. G. O'Bryan
    Shan, M.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 59
  • [40] Radium-223 dichloride (Ra-223) improves survival in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets): nursing roles in implementing this new treatment (tx) option
    Causer, L.
    Johnson, B.
    Sicari, R.
    Lavent, F.
    Lien, L. M. E.
    Jensen, T.
    Wahba, M.
    Parker, C.
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2014, 18 : S21 - S21
12345